Press Release: Cumberland Pharmaceuticals Files for $115 Million IPO
Cumberland Pharmaceuticals Files for $115 Million IPO NASHVILLE, Tenn., May 1 -- Cumberland Pharmaceuticals today announced it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares to be sold in the offering will be offered by Cumberland. The number of shares to be offered and the price range for the offering have not yet been determined. UBS Investment Bank will serve as the sole book-running manager for the offering. Jefferies & Company, Inc., Wachovia Securities and Morgan Joseph will act as co-managers for the offering. The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from the prospectus department of UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, New York 10171 (telephone number 212-821-3000). A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland's primary target markets include hospital acute care and gastroenterology. Cumberland markets AcetadoteÂ® for the treatment of acetaminophen poisoning and KristaloseÂ®, a prescription strength laxative. The Company is also developing AmeliorÂ® which is in Phase III studies for the treatment of both pain and fever. Cumberland is dedicated to providing innovative products which improve quality of care for patients.